Nordicus Partners Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Henrik Rouf
- Full Time Employees
- 15
- Sector
- Industrials
- Industry
- Consulting Services
- Address
- 280 South Beverly Dr Beverly Hills CA United States of America 90212
- IPO Date
- Jun 12, 1996
- CIK
- 0001011060
- Website
- nordicuspartners.com
- Similar Companies
- Business
- Nordicus Partners Corporation is a financial consulting firm specializing in enabling Nordic and U.S. life sciences companies to establish a footprint in the United States market. The company provides a broad range of corporate finance services, including business valuation; growth strategy and budgeting; preparation of investment memorandums; capital-raising support; facilitation of reverse takeovers and M&A activity; and advisory on acquisitions and sales. Nordicus also operates as a startup incubator and advisor to ventures across green energy/clean tech, life sciences, e-commerce, blockchain, and software-as-a-service sectors. Founded in 1993, the firm is headquartered in Beverly Hills, California, and maintains a presence focused on cross-border market entry, strategic partnerships, and capital markets access for Nordic and international clients. The company’s larger strategy includes pursuing Nasdaq uplisting opportunities and expanding its Nordic accelerator client base while exploring high-growth acquisition targets within its core sectors. Nordicus serves corporate clients domestically and globally, with subsidiaries in related life sciences ventures such as Oricidin, Bio-Convert, and NoviThera, as part of its ongoing operational and strategic initiatives. The firm’s structure supports advisory services, financing strategies, and growth enablement across its primary geographic and sector focuses. Nordicus also identifies opportunities for reverse mergers, capital raising, and strategic exits, aiming to drive value creation through structured, client-centric engagements. The company’s brand positioning emphasizes bridging Nordic innovation with U.S. market access, utilizing its network and transaction expertise to facilitate financing, market entry, and strategic growth for its clients. Nordicus operates under the ticker NORD on OTC markets, reflecting its ongoing development as a financial consultancy with expansion ambitions into larger capital markets platforms. The company reports and updates frequently on corporate progress, including subsidiary developments, market expansion, and efforts toward uplisting and broader strategic collaborations.
Nordicus Partners Corporation Corporate Update
Nordicus Partners Corporation Corporate Update
Nordicus Partners Corporation Corporate Update
Nordique Announces Change in CEO and Director
NoviThera has initiated the first efficacy animal studies
Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.
Orocidin develops novel cGMP manufacturing process in collaboration with Syngene
Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS
Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market
Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors
Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia
Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in Dogs
Orocidin and Syngene Partner to Accelerate Biotech Innovation
Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study
Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia
Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment
Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin's Breakthrough Treatment for Periodontitis
Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025
NORDICUS now trading under symbol NORD
Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S